Recombinant Mouse SEMA4B Protein
Beta LifeScience
SKU/CAT #: BLK-01411P-100UG

Mouse SEMA4B on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Mouse SEMA4B Protein
Beta LifeScience
SKU/CAT #: BLK-01411P-100UG
Collections: High-quality recombinant proteins, Other recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Mouse SEMA4B Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Leu31-Glu703. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | Q62179 |
Target Symbol | SEMA4B |
Synonyms | Semaphorin-4B; Semaphorin-C; SEMA4B; KIAA1745; SEMAC; MGC131831; SemC |
Species | Mouse |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Leu31-Glu703 |
Mol. Weight | The protein has a predicted MW of 75.7 kDa. Due to glycosylation, the protein migrates to 78-83 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Semaphorin 4B (SEMA4B) inhibits the invasion of non-small cell lung cancer (NSCLC) through PI3K-dependent suppression of MMP9 activation. SEMA4B may induce FoxO1 nuclear retention through suppressing PI3K/Akt signaling pathway, which subsequently inhibited cell growth through the direct nuclear target of FoxO1, p21. A role of SEMA4B in suppressing NSCLC growth, besides its role in inhibiting cell metastasis, and highlights SEMA4B as a promising therapeutic target for NSCLC. |